IMU.ASX: Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

Stock	Imugene Ltd (IMU.ASX)
Release Time	22 May 2026, 9:27 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Imugene Ltd. Presents Promising Azer-cel Data at ASCO 2026

Key Points

Azer-cel shows promising clinical activity in CAR T-naive cohort
Overall response rate of 81% among evaluable patients
Encouraging responses across various blood cancer types
Abstract available at asco.org/abstracts
Oral presentation on 29 May 2026

Full Summary

Imugene Limited (ASX:IMU) announced promising results from its azer-cel Phase 1b study, which were published in the American Society of Clinical Oncology (ASCO) abstract. The study, conducted in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy, showed an overall response rate of 81% among the evaluable patients. Responses were observed across multiple lymphoma and leukemia subtypes, including diffuse large B-cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, primary central nervous system lymphoma, follicular lymphoma, and Waldenström macroglobulinemia. Imugene will present updated data during an oral presentation at ASCO on 29 May 2026.